William Ashton - Jul 22, 2025 Form 4 Insider Report for Medicus Pharma Ltd. (MDCX)

Role
Director
Signature
/s/ Raza Bokhari, as Attorney-in-Fact, for William L. Ashton
Stock symbol
MDCX
Transactions as of
Jul 22, 2025
Transactions value $
$0
Form type
4
Date filed
7/24/2025, 05:10 PM
Previous filing
Jan 23, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ashton William Director 300 CONSHOHOCKEN STATE ROAD, SUITE 200, W. CONSHOHOCKEN /s/ Raza Bokhari, as Attorney-in-Fact, for William L. Ashton 2025-07-24 0001474553

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDCX Stock Option (right to buy) Award $0 +25K $0.00 25K Jul 22, 2025 Common Shares 25K $3.08 Direct F3
holding MDCX Stock Option (right to buy) 15K Jul 22, 2025 Common Shares 15K $2.75 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an exercise price of $3.95 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024.
F2 The board of directors of Medicus Pharma Ltd. (the ?Board?) approved, during a Board meeting held on July 22, 2025, accelerated vesting of the Reporting Person's options that were otherwise unvested and scheduled to vest quarterly in four equal installments over one year from the initial grant date of December 17, 2024. All these options are now vested.
F3 The option was granted on July 22, 2025. The option is scheduled to vest quarterly in four equal installments over one year.